# MajesTEC-2 (NCT04722146)

> A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04722146
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: Teclistamab; Daratumumab; Pomalidomide; Lenalidomide; Bortezomib; Nirogacestat
- Enrollment: 140
- Primary outcome: Number of Participants with Incidence of Adverse Events (AEs)
- Primary outcome: Number of Participants with AEs by Severity
- Primary outcome: Number of Participants with Abnormalities in Laboratory Values
- Primary outcome: Number of Participants with Dose-Limiting Toxicity (DLT)

## Commentary we found

- Podcasts: 17
- YouTube: 11
- X threads: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=majestec-2-nct04722146

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04722146", "email": "<work email>"}; the inbox owner confirms by the emailed link.